NuVasive Receives Expanded Clearance From FDA For Precice Limb Lengthening Solution

NuVasive, Inc. (NUVA) announced it received 510(k) clearance from the FDA for the use of its Precice all-internal limb lengthening solution to include pediatric patients. Precice is a magnetically adjustable technology that utilizes an external remote to non-invasively lengthen implants.

"Everyone faced with limb length discrepancy, especially pediatric patients, should have access to a non-invasive limb lengthening solution," said Pete Ligotti, leader of NuVasive Specialized Orthopedics.

NuVasive noted that the Precice nail has been implanted more than 15,000 times, by more than 2,000 surgeons, and in nearly 50 countries.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT